Celltrion’s Herzuma receives ‘recommendation for approval’ from European CHMP
On the 15th(local time), Celltrion announced to acquire ‘recommendation for approval’ on all the indications for ‘Herzuma(generic name: trastuzumab, development name: CT-P6),’ an antibody biosimilar for the treatment of breast cancer, from the Committee for Medicinal Products for Human Use(CHMP) ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
